



---

## CCL4/MIP-1 $\beta$ (human) TR-FRET Biomarker Assay Kit

*Powered by Bioauxilium's THUNDER™ TR-FRET Technology*

---

Item No. 500306

[www.caymanchem.com](http://www.caymanchem.com)

Customer Service 800.364.9897

Technical Support 888.526.5351

1180 E. Ellsworth Rd • Ann Arbor, MI • USA

---

## TABLE OF CONTENTS

<b>GENERAL INFORMATION</b>	3	Materials Supplied
	3	Safety Data
	4	Precautions
	4	Before You Start
	4	If You Have Problems
	4	Storage and Stability
	5	THUNDER™ General Information
	6	Materials Needed but Not Supplied
<b>INTRODUCTION</b>	7	Background
	7	About This Assay
	8	Principle Of This Assay
<b>PRE-ASSAY PREPARATION</b>	9	Reagent Preparation
	13	Sample Preparation
<b>ASSAY PROTOCOL</b>	14	Workflow
	14	Performing the Assay
	15	TR-FRET Plate Reader Settings
<b>ANALYSIS</b>	16	Calculations
	17	Performance Characteristics
<b>RESOURCES</b>	25	References
	26	Notes
	27	Warranty and Limitation of Remedy

## GENERAL INFORMATION

### Materials Supplied

Item Number	Item Name	96 wells Quantity/Size	480 wells Quantity/Size
400620	Europium-Labeled CCL4/MIP-1 $\beta$ Antibody	1 vial/5 $\mu$ l	1 vial/25 $\mu$ l
400623	Acceptor-Labeled CCL4/MIP-1 $\beta$ Antibody	1 vial/20 $\mu$ l	1 vial/100 $\mu$ l
400626	Assay Buffer 3 (5X)	1 vial/1 ml	3 vials/1 ml

To request this kit in bulk quantities, please contact our Sales department. If any of the items listed above are damaged or missing, please contact our Customer Service department. Sales and Customer Service departments can be reached at (800) 364-9897 or (734) 971-3335. We cannot accept any returns without prior authorization.



**WARNING: THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.**

### Safety Data

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent *via* email to your institution.

## Precautions

**Please read these instructions carefully before beginning this assay.**

Do not mix or substitute reagents or materials from other kit lots or kits. Kits are quality control tested as a set of components and performance cannot be guaranteed if utilized separately or substituted.

We cannot guarantee the performance of the product outside the conditions detailed in this kit booklet.

## Before You Start

**Please note the following:**

ONLY white plates should be used for TR-FRET.

DO NOT modify the assay protocol or volumes.

## If You Have Problems

### **Technical Service Contact Information**

Phone: 888-526-5351 (USA and Canada only) or 734-975-3888

Email: techserv@caymanchem.com

In order for our staff to assist you quickly and efficiently, please be ready to supply the lot number of the kit (found on the outside of the box).

## Storage and Stability

This kit will perform as specified if stored as directed at -80°C and used before the expiration date indicated on the outside of the box.

## THUNDER™ General Information

THUNDER™ TR-FRET Biomarker Assay Kits are designed for the quantitative measurement of human cytokines in cell culture supernatants using homogeneous (no wash) TR-FRET technology.

THUNDER™ TR-FRET Biomarker Assay Kits are based on Bioauxilium's enhanced proprietary time-resolved Förster resonance energy transfer (TR-FRET) technology. THUNDER™ assays can be read on most commercially available TR-FRET-compatible plate readers (a list of suitable TR-FRET readers can be found at [www.Bioauxilium.com](http://www.Bioauxilium.com)). TR-FRET-based assays are homogeneous because they do not require any washing or separation steps. In addition, the THUNDER™ assays use a standardized, simple, and rapid "add-incubate-measure" protocol with a single step reagent addition. This streamlined assay protocol dramatically decreases hands-on time and provides a powerful alternative to cumbersome, error-prone and time-consuming techniques such as Western blot and ELISA.

THUNDER™ TR-FRET Biomarker Assay Kits do not require the addition of potassium fluoride to ensure signal stability. The non-toxic nature of THUNDER™ kits make them ideal candidates for multiplexing with other assay technologies using a sequential assay protocol.

THUNDER™ TR-FRET Biomarker Assay Kits contain the essential reagents necessary to carry out the measurement of human cytokines in cell culture supernatants, with the exception of the standard and the plate(s).

## Materials Needed But Not Supplied

1. A plate reader equipped with a TR-FRET option
2. Adjustable pipettes; multichannel or repeating pipettor recommended
3. A source of ultrapure water, with a resistivity of 18.2 MΩ·cm and total organic carbon (TOC) levels of <10 ppb, is recommended. Pure water - glass-distilled or deionized - may not be acceptable. *NOTE: UltraPure Water is available for purchase from Cayman (Item No. 400000).*
4. Low-volume 384-well, or half-area 96-well, white plates
5. Recombinant human CCL4/MIP-1β standard, available from R&D Systems® (Catalog No. 8228-MB).
6. Adhesive sealing film for plates

## INTRODUCTION

### Background


Chemokine (C-C motif) ligand 4 (CCL4), also known as macrophage inflammatory protein 1β (MIP-1β), is a pro-inflammatory chemokine with roles in immune cell recruitment.<sup>1,2</sup> It is produced by macrophages, T and B cells, neutrophils, dendritic cells, mast cells, and natural killer (NK) cells in response to stimulation by pro-inflammatory cytokines, LPS, substance P, or viral infection.<sup>3</sup> CCL4 induces signaling via the G protein-coupled receptor chemokine (C-C motif) receptor 5 (CCR5), which leads to activation of various target cell processes, including phagocytosis, chemotaxis, and degranulation.<sup>1,3</sup> Serum and bronchoalveolar (BALF) levels of CCL4 are positively correlated with disease severity in patients with type 2 airway inflammation and corticosteroid resistance in patients asthma, respectively, and serum levels are negatively correlated with disease severity in patients with postmenopausal osteoporosis.<sup>4,5</sup> Polymorphisms in CCL4 are associated with reduced risk of developing hepatocellular carcinoma, reduced tumor size in various oral cancers, and decreased risk of lymph node metastasis in luminal breast cancers.<sup>1</sup>

### About This Assay

This CCL4/MIP-1β (human) TR-FRET Biomarker Assay Kit uses a homogenous TR-FRET sandwich immunoassay method amenable to rapid measurement of CCL4/MIP-1β levels in cell culture supernatants. The standard curve spans a dynamic range of 7-30,000 pg/ml and a lower limit of quantification (LLOQ) of 44 pg/ml using the assay buffer included in the kit with laser excitation. The amount of reagents provided is sufficient for testing either 96 or 480 wells, depending on the size of the kit.

## Principle Of This Assay

This assay is a homogenous TR-FRET-based sandwich immunoassay (Figure 1, below). Native or recombinant human CCL4/MIP-1 $\beta$  in cell culture supernatant samples is detected with a pair of fluorophore-labeled antibodies reactive to human CCL4/MIP-1 $\beta$ .



**Figure 1. Schematic of the TR-FRET biomarker assay principle**

The first antibody is labeled with a long-lifetime donor fluorophore (a europium chelate; Eu-Ab) and the second with a far-red acceptor fluorophore (FR-Ab). The binding of the two labeled antibodies to distinct epitopes on the target cytokine takes place in solution and brings the two dyes into close proximity. Excitation of the donor Eu chelate molecules with a flash lamp (320 or 340 nm) or laser (337 nm) triggers a FRET from the donor to the acceptor molecules, which, in turn, emit a TR-FRET signal at 665 nm. The signal at 665 nm is proportional to the concentration of human CCL4/MIP-1 $\beta$  in the cell culture supernatant. Residual energy from the Eu chelate generates light at 615 nm.

TR-FRET assays exhibit very low background fluorescence levels and high signal-to-background (S/B) ratios. The data can be expressed and analyzed as either the signal at 665 nm or the 665 nm/615 nm ratio. The ratiometric measurement further increases assay reproducibility and robustness.

## PRE-ASSAY PREPARATION

### Reagent Preparation

The instructions described below are for testing the entire number of wells in each kit. Adjust volumes accordingly when testing fewer wells. Prepare only as much reagent as is needed on the day of the assay.

Bring all reagents to room temperature prior to use.

Centrifuge all tubes before use to improve recovery of content (2,000 xg, 10-15 seconds).

Use ultrapure water (18 M $\Omega$ -cm) to dilute the Assay Buffer 3 (5X).

NOTE: It is recommended to test all standards in triplicate and samples at least in duplicate.

#### 1. Assay Buffer 3 (1X)

Mix the Assay Buffer 3 (5X) (Item No. 400626) end-over-end before use. The thawed Assay Buffer 3 (5X) will be stable for 1-2 weeks when stored at 4°C or for longer periods of time when stored at -80°C.

Add 1 ml (96 wells) or 3 ml (480 wells) of Assay Buffer 3 (5X) with 4 ml (96 wells) or 12 ml (480 wells) of ultrapure water. Store unused Assay Buffer 3 (1X) at 4°C; it will be stable for approximately two days.

## 2. CCL4/MIP-1 $\beta$ Standard Serial Dilutions

Recombinant human CCL4/MIP-1 $\beta$  is not included in the kit. The kit has been validated using recombinant human CCL4/MIP-1 $\beta$  from R&D Systems® (Catalog No. 8228-MB). Other commercial recombinant human CCL4/MIP-1 $\beta$  proteins may also work but have not been tested with the kit.

Prepare standard solutions just before use and use within one hour. Do NOT store the standard solutions.

Each well requires 15  $\mu$ l of serially diluted standards.

Reconstitute the analyte following the manufacturer's instructions (typically 100-200  $\mu$ g/ml) to create a stock solution. Dilute the stock solution in either Assay Buffer 3 (1X) or culture medium containing 10% FBS, depending on which will be used for the standard curve dilutions, to create a 1  $\mu$ g/ml CCL4/MIP-1 $\beta$  working stock solution. The working stock solution will be used to prepare a standard dilution series.

*NOTE: If all of the working stock solution will not be used within one hour, aliquot into screw-capped polypropylene vials and store at -80°C for long-term storage. The undiluted stock solution may also be stored at -80°C.*

To prepare the standard solutions for use: obtain 13 clean test tubes and label them #1-13. Alternatively, serial dilutions can be conducted using a 96-well polypropylene plate.

Prepare serial dilutions for the standard curve as indicated in Table 1, on page 11, using either Assay Buffer 3 (1X) or culture medium containing 10% FBS. Change the pipette tip between each standard dilution. Mix each tube thoroughly between each transfer.

Tube	Volume of CCL4/MIP-1 $\beta$ Standard	Volume of Assay Buffer 3 (1X) OR Culture Medium + 10% FBS ( $\mu$ l)	CCL4/MIP-1 $\beta$ in standard curve (g/ml in 15 $\mu$ l)
1	10 $\mu$ l diluted CCL4/MIP-1 $\beta$ (1 $\mu$ g/ml)	90	1.0E-7
2	30 $\mu$ l of tube 1	70	3.0E-8
3	30 $\mu$ l of tube 2	60	1.0E-8
4	30 $\mu$ l of tube 3	70	3.0E-9
5	30 $\mu$ l of tube 4	60	1.0E-9
6	30 $\mu$ l of tube 5	70	3.0E-10
7	30 $\mu$ l of tube 6	60	1.0E-10
8	30 $\mu$ l of tube 7	70	3.0E-11
9	30 $\mu$ l of tube 8	60	1.0E-11
10	30 $\mu$ l of tube 9	70	3.0E-12
11	30 $\mu$ l of tube 10	60	1.0E-12
12	30 $\mu$ l of tube 11	70	3.0E-13
13*	0	60	0

**Table 1. Standard curve serial dilutions**

\*In order to calculate the limit of detection (LOD), three additional zero-standard tubes per plate should be prepared and assayed in triplicate.

### 3. Antibody Working Solutions

*NOTE: Due to the low reagent volumes, the antibodies are diluted with Assay Buffer 3 (1X) directly in the vial when assaying only 96 wells.*

*NOTE: Each well requires 2.5  $\mu$ l of Europium-Labeled CCL4/MIP-1 $\beta$  Antibody (Eu-Ab) (8X) and 2.5  $\mu$ l of Acceptor-Labeled CCL4/MIP-1 $\beta$  Antibody (FR-Ab) (8X).*

Prepare and mix just before use.

#### **For 96 wells:**

Eu-Ab Solution (8X): Add 255  $\mu$ l of Assay Buffer 3 (1X) into the vial containing 5  $\mu$ l of Europium-Labeled CCL4/MIP-1 $\beta$  Antibody (Eu-Ab) (Item No. 400620), and gently mix.

FR-Ab Solution (8X): Add 240  $\mu$ l of Assay Buffer 3 (1X) into the vial containing 20  $\mu$ l of Acceptor-Labeled CCL4/MIP-1 $\beta$  Antibody (FR-Ab) (Item No. 400623), and gently mix.

**OR**

#### **For 480 wells:**

Eu-Ab Solution (8X): Gently mix 25  $\mu$ l of Eu-Ab (Item No. 400620) with 1,275  $\mu$ l Assay Buffer 3 (1X).

FR-Ab Solution (8X): Gently Mix 100  $\mu$ l of FR-Ab (Item No. 400623) with 1,200  $\mu$ l of Assay Buffer 3 (1X).

Store unused Eu-Ab Solution (8X) and FR-Ab Solution (8X) at 4°C; it will be stable for approximately two days. If all unused Eu-Ab Solution (8X) and FR-Ab Solution (8X) will not be used within two days, aliquot and store at -80°C. Avoid repeated freeze/thaw cycles.

### Sample Preparation

Each well requires 15  $\mu$ l of sample (cell culture supernatant).

After collection, place the samples at 4°C and assay immediately or aliquot and store at -80°C.

Avoid repeated freeze/thaw cycles. Thaw samples at room temperature. Do NOT use a water bath to thaw samples.

Prepare serial dilutions using the same media used to culture the cells. If the analyte concentration in the sample possibly exceeds the highest point of the standard curve, prepare one or more 10-fold dilutions of the sample.

## ASSAY PROTOCOL

### Workflow

The THUNDER™ TR-FRET Cell Signaling Assay workflow consists of a one-step assay reagent addition followed by an incubation period.



Figure 2. Assay workflow

### Performing the Assay

Samples and standards **MUST** be assayed at least in duplicate (triplicate recommended) each time the assay is performed.

When loading reagents in the low-volume 384-well microplate, change pipette tips between each standard or sample addition and after each set of reagents.

If using a multichannel pipettor, always use a new disposable reagent reservoir.

When reagents are added to the microplate, ensure the liquids are at the bottom of the well.

1. Add 15 µl of each working standard or 15 µl of the supernatant sample to the designated wells.
2. Add 2.5 µl of Eu-Ab solution (8X) to each of the assay wells.
3. Cover the plate with adhesive plate-sealing film and incubate for 30 minutes at room temperature.
4. Gently remove the adhesive plate-sealing film. Add 2.5 µl of FR-Ab solution (8X) to each of the assay wells.

5. Cover the plate with adhesive plate-sealing film and incubate for 1 hour at room temperature.
6. Gently remove the adhesive plate-sealing film. Read the plate on a TR-FRET-compatible microplate reader (see Table 2, page 15).

**NOTE:** The same plate can be read several times without a negative effect on the assay performance.

### TR-FRET Plate Reader Settings

We recommend reading the TR-FRET assays at two wavelengths, detecting both the emission from the Eu chelate donor fluorophore at 615 nm and the acceptor fluorophore at 665 nm. Table 2, below, provides instrument settings to be used as guidelines.

Parameter	TR-FRET-compatible Plate Reader	
	Flash lamp excitation	Laser excitation
Excitation filter	320 nm (or 340 nm)	N/A
Emission filter	615 nm (or 620 nm)	615 nm (or 620 nm)
Delay time	90 µs	50 µs
Flash energy level	100% or High	100%
Number of flashes	100-200	20
Window (integration time)	300 µs	100 µs

Table 2. Recommended TR-FRET plate reader settings



## Calculations

Because the TR-FRET signal is read in a time-resolved manner, background subtraction is usually not necessary.

Do not use a value of zero for the zero standard. Use the actual background values obtained with the zero standard.

If samples have been diluted, the concentration read from the standard curve must be multiplied by the dilution factor.


1. TR-FRET data are typically calculated and presented ratiometrically using the following formula:

$$[(665 \text{ nm}/615 \text{ nm}) \times 1,000]$$


2. Calculate the TR-FRET ratio for each well. Alternatively, the signals at 665 nm can be used directly to analyze the data.
3. Create a standard curve by analyzing the data according to a nonlinear regression using the four-parameter logistic equation (sigmoidal dose-response curve with variable slope) and a  $1/Y^2$  data weighting. For correct analysis, the highest standard point should be removed from the curve if it is present after the hook point (i.e., if it shows lower counts compared to the next standard).

## Performance Characteristics

### Representative Data



**Figure 3. Typical standard curve using lamp excitation** Data represent the mean  $\pm$  standard deviation of triplicate measurements (three wells) for each standard dilution. The data was generated using a low-volume 384-well white plate read with an EnVision® Multilabel Plate Reader equipped with a TR-FRET option.



**Figure 4. Typical standard curve using laser excitation** Data represent the mean  $\pm$  standard deviation of triplicate measurements (three wells) for each standard dilution. The data was generated using a low-volume 384-well white plate read with an EnVision® Multilabel Plate Reader equipped with a TR-FRET option.

## Sensitivity

The limit of detection (LOD) was calculated by adding two standard deviations to the mean background counts of 12 zero-standard replicates and calculating the corresponding concentration on the standard curve.

The lower limit of quantification (LLOQ) was calculated by adding 10 standard deviations to the mean background counts of 12 zero-standard replicates and calculating the corresponding concentration on the standard curve.

	Assay Buffer 3 (1X)		DMEM + 10% FBS		RPMI + 10% FBS	
	Laser	Lamp	Laser	Lamp	Laser	Lamp
# of Standard Curves	10	10	3	3	3	3
Standard Curves LOD (pg/ml)	7.2	8.6	16.9	38.1	17.9	23.6
LLOQ (pg/ml)	43.7	68.4	93	306	104	169

**Table 3. Sensitivity of the CCL4/MIP-1β (human) TR-FRET Assay Kit**

## Precision

### Intra-assay precision:

Three samples of known concentration (low, medium, high) were tested twenty times each on the same plate to assess intra-assay precision. The assay was run in a 384-well plate with the standards and samples prepared in Assay Buffer 3 (1X). The resulting low %CV (<10%) for each sample indicates good reproducibility within an assay.

	Sample Concentration		
	Low	Medium	High
# of Samples	21	21	21
Mean (pg/ml)	893	2,009	3,058
SD (pg/ml)	66	91	175
CV (%) Intra-Assay	7.4	4.5	5.7

Table 4. Intra-assay precision

### Inter-assay precision:

Three samples of known concentration were tested in separate assays to assess inter-assay precision. A total of seven independent experiments were performed by two operators using two different kit lots: The assay was run in 384-well plates with the standards and samples prepared in Assay Buffer 3 (1X) and tested in triplicate. The resulting low %CV (<10%) for each sample indicates good reproducibility between assays.

	Sample Concentration		
	Low	Medium	High
# of Samples	25	25	25
Mean (pg/ml)	1,039	2,074	2,927
SD (pg/ml)	99	153	286
CV (%) Inter-Assay	9.5	7.4	9.8

Table 5. Inter-assay precision

## Recovery

To assess the accuracy of the assay, spike-to-recovery experiments were conducted using Assay Buffer 3 (1X) and culture media. Each assay consisted of one standard curve and three spike concentrations (low, medium, high) assayed in triplicate in Assay Buffer 3 (1X), DMEM (supplemented with 10% FBS), or RPMI (supplemented with 10% FBS). The percent recovery is reported as the mean concentration of three wells determined using a standard curve prepared in the corresponding diluent. The data shows recovery values within the range of 80-120% demonstrating assay accuracy.

	Spike Level	Expected (pg/ml)	Observed (pg/ml)	% Recovery
Assay Buffer 3 (1X)	High	3,000	3,098	103
	Medium	1,000	975	98
	Low	300	292	97
DMEM + 10% FBS	High	3,000	3,106	104
	Medium	1,000	1,014	101
	Low	300	247	82
RPMI + 10% FBS	High	3,000	3,198	107
	Medium	1,000	1,204	120
	Low	300	305	102

Table 6. Recovery in assay buffer or culture media

## Linearity

To assess the linearity of the assay, a high concentration of CCL4/MIP-1 $\beta$  was spiked into culture medium supplemented with 10% FBS and diluted with the same culture medium with 10% FBS. The assay was run in a 384-well plate with standards prepared in the same type of supplemented culture medium. Each sample was measured in triplicate. Data shows recovery values within 75-125% confirming assay linearity.

	Expected (pg/ml)	Observed (pg/ml)	% Recovery
DMEM + 10% FBS	7,810	6,213	80
	3,910	4,326	111
	1,950	2,230	114
	977	1,221	125
	488	497	105
	244	267	109
	122	119	97
	RPMI + 10% FBS	7,810	5,861
3,910		3,703	95
1,950		2,140	110
977		1,142	117
488		500	102
244		247	101
122		119	98
61		55	90

Table 7. Dilutional linearity in culture medium

Assay Summary		
Assay Type	Homogeneous sandwich immunoassay	
Format	384-well plate	
Hands-on Time	15 minutes	
Incubation Time	1 hour	
Sample Type (Volume)	Cell culture supernatant (15 µl)	
Specificity	Native and recombinant human CCL4/MIP-1β	
	Laser excitation	Lamp excitation
Limit of Detection (LOD)	7 pg/ml	9 pg/ml
Lower Limit of Quantification (LLOQ)	44 pg/ml	68 pg/ml
EC <sub>50</sub> Value	7.1 ng/ml	10.4 ng/ml
Dynamic Range	7-30,000 pg/ml	10-30,000 pg/ml

Table 8. Assay validation summary for the CCL4/MIP-1β (human) TR-FRET Biomarker Assay Kit

## RESOURCES

### References

1. Mukaida, N., Sasaki, S., and Baba, T. CCL4 signaling in the tumor microenvironment in Tumor Microenvironment. The Role of Chemokines - Part A. 23-32 (2020).
2. Korbecki, J., Grochans, S., Gutowska, I., *et al.* CC chemokines in a tumor: A review of pro-cancer and anti-cancer properties of receptors CCR5, CCR6, CCR7, CCR8, CCR9, and CCR10 ligands. *Int. J. Mol. Sci.* **21(20)**, 7619 (2020).
3. Maurer, M. and von Stebut, E. Macrophage inflammatory protein-1. *Int. J. Biochem. Cell Biol.* **36(10)**, 1882-1886 (2004).
4. Kobayashi, Y., Chu, H.H., Kanda, A., *et al.* CCL4 functions as a biomarker of type 2 airway inflammation. *Biomedicines* **10(8)**, 1779 (2022).
5. Maurer, M. and von Stebut, E. Macrophage inflammatory protein-1. *Int. J. Biochem. Cell Biol.* **36(10)**, 1882-1886 (2004).

## NOTES

### Warranty and Limitation of Remedy

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

This document is copyrighted. All rights are reserved. This document may not, in whole or part, be copied, photocopied, reproduced, translated, or reduced to any electronic medium or machine-readable form without prior consent, in writing, from Cayman Chemical Company.

©07/06/2023, Cayman Chemical Company, Ann Arbor, MI, All rights reserved.  
Printed in U.S.A.

